BG
TEVA icon

Bahl & Gaynor’s Teva Pharmaceuticals TEVA Stock Holding History

Bahl & Gaynor’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,355
Closed -$246K – 396
2016
Q3 		$246K Sell
5,355
-55
-1% -$2.87K ﹤0.01% 372
2016
Q2 		$272K Buy
5,410
+5
+0.1% +$266 ﹤0.01% 371
2016
Q1 		$290K Buy
5,405
+360
+7% +$21.1K ﹤0.01% 360
2015
Q4 		$331K Sell
5,045
-32
-0.6% -$1.98K ﹤0.01% 358
2015
Q3 		$287K Sell
5,077
-48
-0.9% -$3.11K ﹤0.01% 376
2015
Q2 		$303K Buy
+5,125
New +$316K ﹤0.01% 388
2014
Q4 		– Sell
-3,920
Closed -$211K – 429
2014
Q3 		$211K Buy
+3,920
New +$208K ﹤0.01% 405
2014
Q2 		– Sell
-8,754
Closed -$462K – 406
2014
Q1 		$462K Sell
8,754
-4,046
-32% -$187K 0.01% 283
2013
Q4 		$513K Sell
12,800
-177,352
-93% -$6.98M 0.01% 262
2013
Q3 		$7.18M Sell
190,152
-7,428
-4% -$290K 0.13% 96
2013
Q2 		$7.75M Buy
+197,580
New +$7.69M 0.15% 94

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Bahl & Gaynor's TEVA Position: Q4 2016 in Review

Bahl & Gaynor sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 5,355 shares — an estimated $246K sold.

Bahl & Gaynor first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $7.75M in Q2 2013. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Bahl & Gaynor reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Bahl & Gaynor sold 5,355 Teva Pharmaceuticals shares in Q4 2016, an estimated $246K.
  • Bahl & Gaynor first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Bahl & Gaynor's Teva Pharmaceuticals position peaked at $7.75M in Q2 2013.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Bahl & Gaynor's 13F filing for Q4 2016, filed 14 Feb 2017.